Clinical Trials Logo

Permanent Atrial Fibrillation clinical trials

View clinical trials related to Permanent Atrial Fibrillation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02695992 Completed - Atrial Fibrillation Clinical Trials

Rate Control in Atrial Fibrillation II

RATAFII
Start date: February 2016
Phase: Phase 4
Study type: Interventional

The RATAF II study is a randomized, prospective, parallel group study, designed to compare the effects of two different drug regimens for rate control in permanent AF (atrial fibrillation). We will investigate on the difference in effects on exercise capacity, biomarkers (NT-proBNP (N-terminal pro-brain natriuretic peptide), troponins, hs-CRP), heart rate, echocardiographic measurements and symptoms. Our main hypothesis is that six months' treatment with the calcium channel blocker diltiazem will lower NT-proBNP and increase exercise capacity (peak VO2) compared to treatment with the beta blocker metoprolol in permanent AF.

NCT ID: NCT02391337 Completed - Clinical trials for Permanent Atrial Fibrillation

Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)

RATE-AF
Start date: December 20, 2016
Phase: Phase 4
Study type: Interventional

Atrial fibrillation is a common heart rhythm disturbance, causing important discomfort for patients, a high risk of stroke, frequent hospital admissions and a two-fold increase in death. The number of patients with this condition are expected to double in the next 20 years. Medications to control heart-rate are used in the majority of patients, although the choice of agent is often guided by local preference rather than evidence from controlled trials. Despite the fact that patients with atrial fibrillation have high rates of other cardiac conditions such as heart failure, clinicians have insufficient evidence to personalise the use of different therapies. This feasibility study will allow us to develop a range of methods that can characterise patients according to the pumping and relaxing function of the heart, the burden of symptoms and to identify new blood markers. In this way, the investigators hope to improve clinical practice guidelines, allowing doctors to prescribe appropriate treatments for the right patients. The research will be focused around a randomised trial of two medication strategies, providing much-needed data on the comparison of digoxin and beta-blockers (two commonly-used drugs in patients with atrial fibrillation). It will also allow us to identify the best way to record patient-reported quality of life and develop robust techniques to determine heart function using non-invasive imaging, facilitating the conduct of a large-scale clinical trial. The key objectives of the research programme are to define the optimal medications for patients with atrial fibrillation and identify the most valid, reproducible and cost-effective methods to examine patients. The ultimate aim of the project is to improve clinical outcomes in atrial fibrillation, benefiting patients, the National Health Service and the global community.

NCT ID: NCT02161965 Completed - Pulmonary Embolism Clinical Trials

Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation

VICTORIA
Start date: May 21, 2013
Phase: Phase 4
Study type: Interventional

The VICTORIA Study (Vascular CalcIfiCation and sTiffness induced by ORal antIcoAgulation) is a comparative, parallel, prospective, controlled and randomized study of the structural and functional impact of rivaroxaban versus anti-vitamin K drugs on the arterial vasculature.

NCT ID: NCT01765075 Completed - Clinical trials for Permanent Atrial Fibrillation

Signal Transfer of Atrial Fibrillation Data to Guide Human Treatment

STARLIGHT
Start date: April 2013
Phase: N/A
Study type: Observational

The purpose of the study is to gather electrophysiological data using a multi-electrode mapping catheter during a clinically indicated cardiac ablation procedure for the treatment of persistent atrial fibrillation.

NCT ID: NCT00246805 Completed - Clinical trials for Permanent Atrial Fibrillation

Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study

RARE-PEARL
Start date: January 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to monitor heart rate regularization in patients with permanent atrial fibrillation and standard indication for single chamber rate adaptive pacing VVI(R).